Supriya Lifescience Limited has informed the Exchange about General Updates on amendment of Policies/code.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Supriya Lifescience's Board, at its meeting on August 13, 2025, approved the unaudited standalone financial results for the quarter ended June 30, 2025. Revenue from operations came in at ₹1,450.74 million, down about 9.7% year-on-year from ₹1,606.26 million in Q1 FY25 and also lower sequentially versus ₹1,841.09 million in Q4 FY25. Net profit fell to ₹347.90 million from ₹446.44 million a year ago, a decline of roughly 22%, while earnings per share dropped to ₹4.32 from ₹5.54. Total expenses were modestly lower at ₹1,003.36 million versus ₹1,030.76 million. Separately, the Board revised three governance documents: the Nomination and Remuneration Policy, the Policy on Determination of Materiality of Events, and the Insider Trading Code, all of which are now available on the company's website.
The double-digit YoY and sequential decline in both revenue and profit is a soft print that may weigh on short-term sentiment; the policy revisions are routine compliance updates and unlikely to move the stock on their own.